Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function

NCT05140239 is registered in ClinicalTrials.gov with Prof. Dr. Stephan Weidinger as lead sponsor.

NCT NCT05140239
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05140239 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Abrocitinib Treatment of Moderate to Severe Atopic Dermatitis on Skin Barrier Function
Lead sponsor
Prof. Dr. Stephan Weidinger
Phase
Observational
Overall status
Completed
Start date
September 1, 2022
Completion date
December 31, 2024
Enrollment
20 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

atopic dermatitis